Clinical outcomes of transcarotid artery revascularization vs carotid endarterectomy from a large single-center experience

医学 颈动脉内膜切除术 冲程(发动机) 围手术期 血运重建 心力衰竭 内科学 心脏病学 心肌梗塞 外科 狭窄 机械工程 工程类
作者
Ali F. AbuRahma,Adrian Santini,Zachary AbuRahma,Andrew Lee,Christina Veith,Noah Dargy,Robert Cragon,Scott L. Dean,E Mattox
出处
期刊:Journal of Vascular Surgery [Elsevier]
标识
DOI:10.1016/j.jvs.2024.01.213
摘要

Abstract

Background

Transcarotid artery revascularization (TCAR) has been practiced as an alternative for both carotid endarterectomy (CEA) and transfemoral carotid artery stenting, specifically in high-risk patients. More recently, the Centers for Medicare and Medicaid Services expanded coverage for TCAR in standard surgical risk patients if done within the Society for Vascular Surgery Vascular Quality Initiative TCAR surveillance project. A few registry studies (primarily from the Society for Vascular Surgery Vascular Quality Initiative) compared the early and up to 1-year outcomes of TCAR vs CEA or transfemoral carotid artery stenting. There is no large single-center study that reported late clinical outcomes. The present study compares intermediate clinical outcomes of TCAR vs CEA.

Methods

This study retrospectively analyzed collected data from TCAR surveillance project patients enrolled in our institution and compare it with CEA patients done by the same providers at the same time period. The primary outcome was combined perioperative stroke/death and late stroke/death. Secondary outcomes included combined stroke, death, and myocardial infarction, cranial nerve injury (CNI), and bleeding. Propensity matching was done to analyze outcome. Kaplan-Meier analysis was used to estimate freedom from stroke, stroke/death, and ≥50% and ≥80% restenosis.

Results

We analyzed 646 procedures (637 patients) (404 CEA, 242 TCAR). There was no significant difference in the indications for carotid intervention. However, TCAR patients had more high-risk criteria, including hypertension, coronary artery disease, congestive heart failure, and renal failure. There was no significant differences between CEA vs TCAR in 30-day perioperative stroke (1% vs 2%), stroke/death rate (1% vs 3%; P = .0849), or major hematomas (2% vs 2%). The rate of CNI was significantly different (5% for CEA vs 1% for TCAR; P = .0138). At late follow-up (2 years), the rate of stroke was 1% vs 4% (P = .0273), stroke/death 8% vs 15% (P = .008), ≥80 % restenosis 0.5% vs 3% (P = .0139) for CEA patients vs TCAR patients, respectively. After matching 242 CEAs and 242 TCARs, the perioperative stroke rate was 1% for CEA vs 2% for TCAR (P = .5037), the stroke/death rate was 2% vs 3% (P = .2423), and the CNI rate was 3% vs 1% (P = .127). At late follow-up, rates of stroke were 1% for CEA vs 4% for TCAR (P = .0615) and stroke/death were 8% vs 15% (P = .0345). The rate of ≥80% restenosis was 0.9% for CEA vs 3% for TCAR (P = .099). The rates of freedom from stroke at 6, 12, 18, and 24 months for CEA vs TCAR were 99%, 99%, 99%, and 99% vs 97%, 95%, 93% and 93%, respectively (P = .0806); stroke/death were 94%, 90%, 87%, and 86% vs 93%, 87%, 76%, and 75%, respectively (P = .0529); and ≥80% restenosis were 100%, 99%, 98%, and 98% vs 97%, 95%, 93%, and 93%, respectively (P = .1132).

Conclusions

In a propensity-matched analysis, both CEA and TCAR have similar perioperative clinical outcomes. However, CEA was superior to TCAR for the rates of late stroke/death and had a somewhat lower rate of ≥80% restenosis at 2 years, but this difference was not statistically significant.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zjuroc发布了新的文献求助20
刚刚
坦率的松发布了新的文献求助10
刚刚
xiaokai完成签到,获得积分10
刚刚
刚刚
刚刚
Czy完成签到,获得积分10
刚刚
1秒前
小满完成签到,获得积分10
1秒前
文忉嫣完成签到,获得积分10
1秒前
1秒前
2秒前
落后秋柳完成签到,获得积分20
2秒前
Akim应助zz采纳,获得10
2秒前
3秒前
三九发布了新的文献求助10
4秒前
科研通AI5应助czq采纳,获得30
4秒前
5秒前
5秒前
5秒前
坦率的松完成签到,获得积分10
5秒前
传奇3应助贤惠的正豪采纳,获得10
6秒前
111发布了新的文献求助10
6秒前
三寒鸦完成签到,获得积分10
6秒前
小木棉发布了新的文献求助10
6秒前
6秒前
少年郎完成签到,获得积分20
7秒前
CipherSage应助123lura采纳,获得10
7秒前
七七完成签到,获得积分10
7秒前
科研通AI2S应助小余采纳,获得10
7秒前
苹果骑士完成签到,获得积分10
7秒前
7秒前
shi hui应助jbhb采纳,获得10
8秒前
8秒前
8秒前
JUSTs0so发布了新的文献求助10
8秒前
长夜变清早完成签到,获得积分10
9秒前
10秒前
10秒前
otaro发布了新的文献求助10
11秒前
yinbin完成签到,获得积分10
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762